Table 5.
Cardiovascular disease (CVD) conditions at Wave 2 by Wave 1 WHO risk drinking level and change in WHO risk level between Waves 1 and 2.
| Wave 1 WHO risk level and change by Wave 2 |
Hypertension | |||
|---|---|---|---|---|
| n | Adjusted Prevalence at W2 |
Adjusted OR (95% CI) |
p-value | |
| Wave 1 Very high risk | ||||
| Not decreased by ≧2 levels | 214 | 21.1% | Reference | |
| Decreased by ≧2 levels | 298 | 12.3% | 0.52 (0.38-0.72) | <.0001 |
| Wave 1 High risk | ||||
| Not decreased by ≧2 levels | 266 | 16.0% | Reference | |
| Decreased by ≧2 levels | 280 | 15.8% | 0.98 (0.81-1.19) | 0.8628 |
| Wave 1 WHO risk level and change by Wave 2 |
Arteriosclerosis | |||
| n | Adjusted Prevalence at Wave 2 |
Adjusted OR (95% CI) |
p-value | |
| Wave 1 Very high risk | ||||
| Not decreased by ≧2 levels | 214 | 0.0% | Reference | |
| Decreased by ≧2 levels | 298 | 0.0% | 1.03 (0.40-2.65) | 0.9476 |
| Wave 1 High risk | ||||
| Not decreased by ≧2 levels | 266 | 0.0% | Reference | |
| Decreased by ≧2 levels | 280 | 0.0% | 1.21 (0.43-3.41) | 0.7149 |
| Wave 1 WHO risk level and change by Wave 2 |
Angina | |||
| n | Adjusted Prevalence at Wave 2 |
Adjusted OR (95% CI) |
p-value | |
| Wave 1 Very high risk | ||||
| Not decreased by ≧2 levels | 214 | 0.7% | Reference | |
| Decreased by ≧2 levels | 298 | 1.9% | 2.98 (1.32-6.73) | 0.0084 |
| Wave 1 High risk | ||||
| Not decreased by ≧2 levels | 266 | 1.7% | Reference | |
| Decreased by ≧2 levels | 280 | 0.9% | 0.51 (0.30-0.88) | 0.0154 |
| Wave 1 WHO risk level and change by Wave 2 |
Tachycardia | |||
| n | Adjusted Prevalence at Wave 2 |
Adjusted OR (95% CI) |
p-value | |
| Wave 1 Very high risk | ||||
| Not decreased by ≧2 levels | 214 | 2.9% | Reference | |
| Decreased by ≧2 levels | 298 | 2.5% | 0.85 (0.59-1.21) | 0.3636 |
| Wave 1 High risk | ||||
| Not decreased by ≧2 levels | 266 | 2.1% | Reference | |
| Decreased by ≧2 levels | 280 | 1.9% | 0.92 (0.78-1.08) | 0.2997 |
| Wave 1 WHO risk level and change by Wave 2 |
Myocardial infarctionb | |||
| n | Adjusted Prevalence at Wave 2 |
Adjusted OR (95% CI) |
p-value | |
| Wave 1 Very high risk | ||||
| Not decreased by ≧2 levels | 214 | 0.02% | Reference | |
| Decreased by ≧2 levels | 298 | 0.04% | 2.31 (0.58-9.15) | 0.2323 |
| Wave 1 High risk | ||||
| Not decreased by ≧2 levels | 266 | 0.03% | Reference | |
| Decreased by ≧2 levels | 280 | 0.00% | 0.10 (0.05-0.19) | <.0001 |
| Wave 1 WHO risk level and change by Wave 2 |
Other CVD | |||
| n | Adjusted Prevalence at Wave 2 |
Adjusted OR (95% CI) |
p-value | |
| Wave 1 Very high risk | ||||
| Not decreased by ≧2 levels | 214 | 0.4% | Reference | |
| Decreased by ≧2 levels | 298 | 0.3% | 0.79 (0.32-1.99) | 0.6215 |
| Wave 1 High risk | ||||
| Not decreased by ≧2 levels | 266 | 0.5% | Reference | |
| Decreased by ≧2 levels | 280 | 0.2% | 0.38 (0.18-0.78) | 0.009 |
a
Prevalence values are calculated from the same logistic regression used to obtain adjusted OR values which controls for a priori control covariates (sex, age, education, race and ethnicity, smoking, body-mass index, health insurance, presence of psychiatric condition, respective CVD condition).
b
Results of prevalence levels for myocardial infarction are reported out to two decimal places because of its low prevalence.